J2185
J2185 – Injection, meropenem, 100 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 46 NDCs crosswalked per 100 MG $0.325/unit ASP+6%
📋 J2185 summary
J2185 is a HCPCS Level II J-code used to bill meropenem, 100 mg, billed per 100 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J2185: Meropenem(J2185), Meropenem And Sodium Chloride
Code J2185
Billing unit 100 MG Payment limit $0.325/unit NDC-Crosswalk 46
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ2185
DescriptorInjection, meropenem, 100 mg
Billing unit100 MG
Payment limit / unit$0.325
Est. ASP / unit$0.307 est.
Mapped NDCs46
Data periodQ3 2026
Last updated2026-08-20
💊 About Meropenem DRUG GUIDE
Meropenem for injection is used intravenously to treat three types of serious bacterial infections.
For adults and children 3 months and older, it treats complicated skin and skin structure infections.
For adults and children of all ages, it treats complicated intra-abdominal infections such as complicated appendicitis and peritonitis.
Bacterial meningitis (infection of the lining around the brain and spinal cord) in children 3 months and older is also an approved use.Meropenem should only be used when a bacterial infection is proven or strongly suspected.
Clinical overview from our editorial drug guide for Meropenem. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$0.325
Est. ASP / unit
$0.307 est.
Est. after 2% sequester
$0.319
HCPCS dosage
100 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, meropenem, 100 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2004-01-01
Date added2004-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J2185 = 100 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J2185 LEAST EXPENSIVE FIRST
46 NDCs map to J2185. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($0.325/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 00143-9431-10 | Meropenem 1 g/30mL INJECTION | Hikma | 10 VIAL in 1 CARTON (0143-9431-10) / 30 m... | 1 g/30mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 00409-1391-22 | Meropenem 1 g/20mL INJECTION, POWDER, FOR SOLUTION | Hospira, | 10 VIAL in 1 CARTON (0409-1391-22) / 20 m... | 1 g/20mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 00409-3412-10 | Meropenem 1 g/20mL INJECTION, POWDER, FOR SOLUTION | Hospira, | 10 VIAL in 1 CARTON (0409-3412-10) / 20 m... | 1 g/20mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 00781-3098-95 | MEROPENEM 1 g/30mL INJECTION | Sandoz | 10 VIAL in 1 CARTON (0781-3098-95) / 30 m... | 1 g/30mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 44567-0146-10 | Meropenem 1 g/1 INJECTION, POWDER, FOR SOLUTION | WG | 10 VIAL in 1 CARTON (44567-146-10) / 1 IN... | 1 g/1 | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 44567-0401-10 | Meropenem 1 g/1 INJECTION, POWDER, FOR SOLUTION | WG | 10 VIAL in 1 CARTON (44567-401-10) / 1 IN... | 1 g/1 | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 55150-0208-30 | Meropenem 1 g/1 INJECTION, POWDER, FOR SOLUTION | Eugia | 10 VIAL in 1 CARTON (55150-208-30) / 1 IN... | 1 g/1 | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 63323-0508-30 | Meropenem 1 g/20mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 10 VIAL in 1 CARTON (63323-508-30) / 20 m... | 1 g/20mL | 100 | $32.50 | $4.669 | ● Active | CMS ASP |
| 63323-0508-31 | Meropenem 1 g/20mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 10 VIAL in 1 CARTON (63323-508-31) / 20 m... | 1 g/20mL | 100 | $32.50 | $4.669 | ● Active | CMS ASP |
| 70121-1453-07 | Meropenem 1 g/30mL INJECTION, POWDER, FOR SOLUTION | Amneal | 10 VIAL, GLASS in 1 CARTON (70121-1453-7)... | 1 g/30mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 70594-0076-02 | MEROPENEM 1 g/1 INJECTION, POWDER, FOR SOLUTION | Xellia | 10 VIAL, GLASS in 1 CARTON (70594-076-02)... | 1 g/1 | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 72485-0412-10 | Meropenem 1 g/20mL INJECTION | ARMAS | 10 VIAL in 1 CARTON (72485-412-10) / 20 m... | 1 g/20mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 72572-0416-10 | MEROPENEM 1 g/30mL INJECTION | Civica, | 10 VIAL in 1 CARTON (72572-416-10) / 30 m... | 1 g/30mL | 100 | $32.50 | $4.669 | ● Active | CMS + PDAC |
| 00143-9430-10 | Meropenem 500 mg/20mL INJECTION | Hikma | 10 VIAL in 1 CARTON (0143-9430-10) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 00409-0222-10 | Meropenem 500 mg/10mL INJECTION, POWDER, FOR SOLUTION | Hospira, | 10 VIAL in 1 CARTON (0409-0222-10) / 10 m... | 500 mg/10mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 00409-1390-51 | Meropenem 500 mg/10mL INJECTION, POWDER, FOR SOLUTION | Hospira, | 10 VIAL in 1 CARTON (0409-1390-51) / 10 m... | 500 mg/10mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 00781-3000-95 | MEROPENEM 500 mg/20mL INJECTION | Sandoz | 10 VIAL in 1 CARTON (0781-3000-95) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 25021-0160-20 | Meropenem 500 mg/20mL INJECTION, POWDER, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-160-20) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 44567-0145-10 | Meropenem 500 mg/1 INJECTION, POWDER, FOR SOLUTION | WG | 10 VIAL in 1 CARTON (44567-145-10) / 1 IN... | 500 mg/1 | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 44567-0400-10 | Meropenem 500 mg/1 INJECTION, POWDER, FOR SOLUTION | WG | 10 VIAL in 1 CARTON (44567-400-10) / 1 IN... | 500 mg/1 | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 55150-0207-20 | Meropenem 500 mg/1 INJECTION, POWDER, FOR SOLUTION | Eugia | 10 VIAL in 1 CARTON (55150-207-20) / 1 IN... | 500 mg/1 | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 63323-0507-20 | Meropenem 500 mg/10mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 10 VIAL in 1 CARTON (63323-507-20) / 10 m... | 500 mg/10mL | 50 | $16.25 | — | ● Active | CMS ASP |
| 63323-0507-21 | Meropenem 500 mg/10mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 10 VIAL in 1 CARTON (63323-507-21) / 10 m... | 500 mg/10mL | 50 | $16.25 | — | ● Active | CMS ASP |
| 63323-0507-25 | Meropenem 500 mg/10mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 25 VIAL in 1 CARTON (63323-507-25) / 10 m... | 500 mg/10mL | 125 | $40.63 | — | ● Active | CMS ASP |
| 63323-0508-25 | Meropenem 1 g/20mL INJECTION, POWDER, FOR SOLUTION | Fresenius | 25 VIAL in 1 CARTON (63323-508-25) / 20 m... | 1 g/20mL | 250 | $81.25 | — | ● Active | CMS ASP |
| 70121-1454-07 | Meropenem 500 mg/20mL INJECTION, POWDER, FOR SOLUTION | Amneal | 10 VIAL, GLASS in 1 CARTON (70121-1454-7)... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 70594-0075-02 | MEROPENEM 500 mg/1 INJECTION, POWDER, FOR SOLUTION | Xellia | 10 VIAL, GLASS in 1 CARTON (70594-075-02)... | 500 mg/1 | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 72485-0411-10 | Meropenem 500 mg/20mL INJECTION | ARMAS | 10 VIAL in 1 CARTON (72485-411-10) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 72572-0410-10 | Meropenem 1 g/20mL INJECTION | Civica, | 10 VIAL in 1 CARTON (72572-410-10) / 20 m... | 1 g/20mL | 100 | $32.50 | — | ● Active | CMS + PDAC |
| 72572-0412-10 | Meropenem 500 mg/20mL INJECTION | Civica, | 10 VIAL in 1 CARTON (72572-412-10) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 72572-0415-10 | MEROPENEM 500 mg/20mL INJECTION | Civica, | 10 VIAL in 1 CARTON (72572-415-10) / 20 m... | 500 mg/20mL | 50 | $16.25 | — | ● Active | CMS + PDAC |
| 25021-0161-30 | Meropenem 1 g/30mL INJECTION, POWDER, FOR SOLUTION | Sagent | 10 VIAL in 1 CARTON (25021-161-30) / 30 m... | 1 g/30mL | 10 | $3.25 | — | ● Active | PDAC |
| 00781-3000-96 | MEROPENEM 500 mg/20mL INJECTION | Sandoz | 25 VIAL in 1 CARTON (0781-3000-96) / 20 m... | 500 mg/20mL | 5 | $1.63 | — | ● Active | PDAC |
| 00781-3098-96 | MEROPENEM 1 g/30mL INJECTION | Sandoz | 25 VIAL in 1 CARTON (0781-3098-96) / 30 m... | 1 g/30mL | 10 | $3.25 | — | ● Active | PDAC |
| 68001-0446-31 | MEROPENEM (SDV,USP) 500 MG | Unknown | — | — | 5 | $1.63 | — | — | PDAC |
| 68001-0447-57 | MEROPENEM (SDV,USP) 1 GM | Unknown | — | — | 10 | $3.25 | — | — | PDAC |
| 71288-0014-21 | MEROPENEM (SDV, USP,PF,LATEX-FREE) 500 MG | Unknown | — | — | 5 | $1.63 | — | — | PDAC |
| 71288-0015-31 | MEROPENEM (SDV, USP,PF,LATEX-FREE) 1 GM | Unknown | — | — | 10 | $3.25 | — | — | PDAC |
| 00069-0313-10 | MERREM IV 500 MG | Unknown | — | — | 5 | $1.63 | — | — | PDAC |
| 00069-0314-10 | MERREM IV 1 GM | Unknown | — | — | 10 | $3.25 | — | — | PDAC |
| 68001-0324-57 | MEROPENEM (SDV,USP) 1 GM | Unknown | — | — | 10 | $3.25 | — | — | PDAC |
| 68001-0323-31 | MEROPENEM (SDV,USP) 500 MG | Unknown | — | — | 5 | $1.63 | — | — | PDAC |
| 00264-3185-11 | Meropenem and Sodium Chloride 1 g/50mL INJECTION, SOLUTION | B. | 24 CONTAINER in 1 CASE (0264-3185-11) / 5... | 1 g/50mL | 10 | $3.25 | — | ● Active | PDAC |
| 00264-3183-11 | Meropenem and Sodium Chloride 500 mg/50mL INJECTION, SOLUTION | B. | 24 CONTAINER in 1 CASE (0264-3183-11) / 5... | 500 mg/50mL | 5 | $1.63 | — | ● Active | PDAC |
| 00310-0325-20 | MERREM IV (VIAL) 500 MG | Unknown | — | — | 5 | $1.63 | — | — | PDAC |
| 00310-0321-30 | MERREM IV (VIAL) 1 GM | Unknown | — | — | 10 | $3.25 | — | — | PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$28.1K
Claims
3,378
Beneficiaries
357
Spend / beneficiary
$78.59
Spend / claim
$8.31
Trend by period
Where J2185 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #634 of 824
#629
TOPOTECAN HCL J9351
$32.4K
#630
GRANISETRON HCL J1626
$31.5K
#631
DUAL LAYER IMPAX, PE... Q4262
$31K
#632
CEFEPIME HCL J0692
$30.3K
#633
MODERNA COVID (6M-1... 91321
$30.1K
#634
MEROPENEM(J2185) J2185
$28.1K
#635
CYGNUS, PER SQ CM** Q4170
$28K
#636
CROMOLYN SODIUM J7631
$27.6K
#637
LINCOCIN* J2010
$27.1K
#638
ARANESP(J0882) J0882
$25.4K
#639
VINCASAR PFS* J9370
$24.6K
Total claims — #260 of 824
#255
ALBUKED-5* P9045
3,517
#256
CYCLOSPORINE MODIFIE... J7502
3,508
#257
POLIVY J9309
3,476
#258
LINCOCIN* J2010
3,471
#259
AVEED J3145
3,421
#260
MEROPENEM(J2185) J2185
3,378
#261
IMDELLTRA J9026
3,377
#262
GLUCAGEN* J1610
3,369
#263
CYRAMZA J9308
3,313
#264
PROHANCE MULTIPACK A9576
3,254
#265
SARCLISA J9227
3,200
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $28.1K | 357 | 3,378 | $78.59 | $8.31 |
| 2025 (Q1-Q4) | $147.3K | 1,100 | 14,941 | $133.94 | $9.86 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$136.7K
Medicare paid
$105.6K
Submitted services
920,198
Denial rate
64.7%
Allowed / service
$0.42
Submitted charges
$7.58M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J2185 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 154,164 services across 7 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J2185
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
46 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J2185 billing FAQ
What is HCPCS code J2185?
J2185 is a HCPCS Level II J-code used to bill Injection, meropenem, 100 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2185?
One unit of J2185 represents 100 MG. Report the number of units equal to the dose administered divided by 100 MG.
How many units of J2185 should I bill?
Divide the dose administered by the code's unit size (100 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2185?
The Medicare Part B payment limit is $0.325 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $0.319 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2185?
46 NDCs currently map to J2185 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2185 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.